JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Search

Certara Inc

Geschlossen

BrancheGesundheitswesen

7.22 -2.04

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

7.19

Max

7.37

Schlüsselkennzahlen

By Trading Economics

Einkommen

3.5M

1.5M

Verkäufe

46K

105M

KGV

Branchendurchschnitt

118.571

84.243

Gewinnspanne

1.458

Angestellte

1,487

EBITDA

-6.5M

23M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+60.03% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

26. Feb. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-557M

1.3B

Vorheriger Eröffnungskurs

9.26

Vorheriger Schlusskurs

7.22

Nachrichtenstimmung

By Acuity

50%

50%

139 / 352 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Certara Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Feb. 2026, 23:57 UTC

Market Talk

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

8. Feb. 2026, 23:47 UTC

Market Talk

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

8. Feb. 2026, 23:43 UTC

Market Talk

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

8. Feb. 2026, 23:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. Feb. 2026, 23:34 UTC

Market Talk

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

8. Feb. 2026, 23:26 UTC

Market Talk

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

8. Feb. 2026, 22:55 UTC

Ergebnisse

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

8. Feb. 2026, 22:55 UTC

Ergebnisse

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

8. Feb. 2026, 22:55 UTC

Ergebnisse

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

8. Feb. 2026, 22:55 UTC

Ergebnisse

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

8. Feb. 2026, 22:55 UTC

Ergebnisse

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

8. Feb. 2026, 22:55 UTC

Ergebnisse

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

8. Feb. 2026, 21:43 UTC

Market Talk

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

8. Feb. 2026, 21:16 UTC

Market Talk

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

8. Feb. 2026, 21:15 UTC

Market Talk

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

7. Feb. 2026, 09:20 UTC

Market Talk

Financial Services Roundup: Market Talk

7. Feb. 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. Feb. 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. Feb. 2026, 02:46 UTC

Akquisitionen, Fusionen, Übernahmen

Big Money, High Anxiety -- Barrons.com

6. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. Feb. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

6. Feb. 2026, 21:40 UTC

Akquisitionen, Fusionen, Übernahmen

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6. Feb. 2026, 21:22 UTC

Market Talk

Mexico's Inflation Seen Accelerating in January -- Market Talk

6. Feb. 2026, 21:17 UTC

Ergebnisse

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6. Feb. 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. Feb. 2026, 21:14 UTC

Akquisitionen, Fusionen, Übernahmen

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6. Feb. 2026, 21:13 UTC

Ergebnisse

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6. Feb. 2026, 21:13 UTC

Ergebnisse

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6. Feb. 2026, 21:04 UTC

Market Talk

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6. Feb. 2026, 20:34 UTC

Ergebnisse

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Peer-Vergleich

Kursveränderung

Certara Inc Prognose

Kursziel

By TipRanks

60.03% Vorteil

12-Monats-Prognose

Durchschnitt 11.57 USD  60.03%

Hoch 13 USD

Tief 9 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Certara Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

9 ratings

6

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

11.27 / 12.79Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Very Strong Bullish Evidence

Langfristig

Strong Bullish Evidence

Stimmung

By Acuity

139 / 352 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat